Background
Pancreatic neuroendocrine tumors (PNETs) present various histologic stages, and their
clinical behavior ranges from benign to highly aggressive. World Health Organization
(WHO) grading categorizes PNETs into 3 groups (G1, G2, and G3) based on proliferative
activity. The aim of this study was to assess the clinical utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in preoperative
differential diagnosis for various histologic grades of PNETs and in predicting postoperative
prognosis in PNET patients.
Methods
We investigated prospectively 36 patients who underwent preoperative FDG-PET, received
surgery for PNETs, and had resected specimens examined via histology. The maximum
standardized uptake value (SUVmax) was determined on FDG-PET, and differentiating power between G1/G2 and G3 PNETs
was examined using various SUVmax cutoff levels. We also evaluated the prognostic impact of FDG-PET findings using
postoperative survival data.
Results
SUVmax significantly correlated with WHO grade (Spearman rank correlation 0.584; P = .0018), and the SUVmax of G3 tumors (5.0 ± 2.5; n = 4) was significantly higher than that of G1/G2 tumors (2.7 ± 1.6; n = 32; P = .0159). Using 2.5 as a cutoff SUVmax, the sensitivity, specificity, and accuracy of differentiating G3 tumors from G1/G2
tumors were 100.0%, 62.5%, and 66.7%, respectively. Furthermore, the SUVmax of FDG-PET (<2.5 vs ≥2.5) was significantly related to postoperative disease-free
survival (P = .0463).
Conclusion
These results suggest that FDG-PET may be useful for differentiating G3 PNETs from
G1/G2 PNETs and for predicting postoperative prognosis in PNET patients. This preliminary
finding is expected to be confirmed by prospective validation with more patients.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Differences in survival by histologic type of pancreatic cancer.Cancer Epidemiol Biomarkers Prev. 2005; 14: 1766-1773
- Update on pancreatic endocrine tumors.Arch Pathol Lab Med. 2006; 130: 963-966
- Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.J Gastroenterol. 2010; 45: 234-243
- One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.J Clin Oncol. 2008; 26: 3063-3072
- WHO classification of tumors of the digestive system (World Health Organization Classification of Tumors).IARC Press, Lyon2010
- Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.Cancer Med. 2013; 2: 701-711
- Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.Cancer. 2008; 113: 256-265
- TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.J Natl Cancer Inst. 2012; 104: 764-777
- Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.Am J Surg Pathol. 2011; 35: 853-860
- Proliferative rate in endoscopic ultrasound fine-needle aspiration of pancreatic endocrine tumors: correlation with clinical behavior.Cancer. 2009; 117: 40-45
- Utility of 18F-FDG PET/CT uptake patterns in Waldeyer's ring for differentiating benign from malignant lesions in lateral pharyngeal recess of nasopharynx.J Nucl Med. 2007; 48: 8-14
- A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules.J Nuclear Med. 2008; 49: 179-185
- Diagnostic value of FDG-PET for lymph node metastasis and outcome of surgery for biliary cancer.J Surg Oncol. 2011; 103: 223-229
- Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.Cancer. 2000; 89: 2547-2554
- Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.Oncol Rep. 2010; 24: 613-620
- Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?.World J Surg. 1998; 22: 588-592
- Somatostatin analogs - from new molecules to new applications.Curr Opin Pharmacol. 2004; 4: 608-613
- Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer.Ann Surg Oncol. 2005; 12: 561-569
- Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer.Nuclear Med commun. 2003; 24: 963-970
- Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET.J Nuclear Med. 1999; 40: 566-573
- Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.Mod Pathol. 2010; 23: 824-833
- Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.J Clin Oncol. 2013; 31: 420-425
- Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.Eur J Nucl Med. 1998; 25: 79-83
- Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to the World Health Organization classification.Oncol Lett. 2010; 1: 155-159
- EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience.Gastrointest Endosc. 2010; 71: 1185-1193
- EUS-FNA predicts 5-year survival in pancreatic endocrine tumors.Gastrointest Endosc. 2009; 70: 907-914
- Cytological Ki-67 in pancreatic endocrine tumours: an opportunity for pre-operative grading.Endocr Relat Cancer. 2008; 15: 175-181
- The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology.Cancer. 2009; 117: 211-216
- Cystic neoplasms of the pancreas with mucin-production.Eur J Surg Oncol. 2005; 31: 282-287
Article info
Publication history
Published online: October 10, 2014
Accepted:
September 10,
2014
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
